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help to prevent and treat metabolic side effects caused by APD therapy.
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KEY POINTS
•

Although some atypical anti-psychotic drugs, particularly olanzapine and
clozapine, have more severe weight gain side-effects, all anti-psychotics
including typical anti-psychotics currently used clinically may cause some
degree of weight gain.

•

There are time-dependent changes of weight gain associated with antipsychotic medication with a three stage time-course development; particularly
rapid weight gain in the initial stage is a good indicator for a long-term
outcome of weight gain and obesity.

•

Accumulated data suggest that increasing appetite and food intake, as well as
delayed satiety signalling, are key behavioural changes related to weight
gain/obesity induced by anti-psychotics.

•

Anti-psychotics may induce insulin resistance, glucose dysregulation, and even
type II diabetes mellitus independent of weight gain and adiposity.

•

There are also time-dependent changes for insulin and glucose dysregulation
associated with anti-psychotic medication.

•

Current evidence from clinical trials in first episode psychotic patients shows
typical anti-psychotics such as haloperidol have relatively high risk for weight
gain/obesity and glucometabolic side-effects.
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•

Monitoring weight gain is important but not enough. A periodic monitoring of
blood sugar may also be required during anti-psychotic therapy, particularly for
drugs with high diabetic liabilities such as olanzapine and clozapine.

•

There are marked individual variations in weight gain and other metabolic sideeffects associated with anti-psychotics. For example, irrespective of the antipsychotic drug, some patients lose weight, some maintain weight and some
gain weight.

•

Mechanisms for anti-psychotic related weight gain, insulin resistance and
glucose dysregulation have yet to be elucidated. Current results suggest that
antagonistic effects of atypical anti-psychotics on serotonin 5-HT2C and
histamine H1 receptors play an important role in weight gain/obesity sideeffects, whereas muscarinic M3 receptors have been identified as most closely
linked with diabetic side-effects. However, blockade of dopamine D2 receptors
may be a common mechanism for these metabolic side-effects in both atypical
and typical anti-psychotics.
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INTRODUCTION
Mental disorders are the greatest overall cause of disability.1 Anti-psychotic drugs
(APDs) are the most widely prescribed medications and are used frequently to control
various mental disorders such as schizophrenia, bipolar disorder, dementia, major
depression, Tourette’s syndrome, eating disorders and even substance abuse.2,

3

Unfortunately, APDs may cause some serious side-effects including extra-pyramidal
and metabolic side-effects. Since typical APDs were introduced into clinics in the
1950s, their side-effects of increasing body weight have been reported, but have
gained less attention because these drugs often have worse and problematic extrapyramidal side-effects.4 In the 1980s-1990s, clozapine, olanzapine and other atypical
APDs with reduced extra-pyramidal side-effects were widely introduced into
psychiatric clinics and currently form the first line of APD treatment.5,

6

Unfortunately, atypical APDs, particularly clozapine and olanzapine, cause serious
metabolic side-effects, such as substantial weight gain, intra-abdominal obesity,
hyperlipidemia, insulin resistance, hyperglycemia, and type II diabetes mellitus
(T2DM).7-10 These adverse effects are a major risk for cardiovascular disease, stroke
and premature death (by 20-30 years).7,

11

In addition to medical consequences,

weight gain and obesity can lead to non-compliance with medication - a primary
problem for the treatment of schizophrenia, since cessation of APD treatment
dramatically (up to 5-times) increases the relapse rate for these patients.12, 13 Given
that the majority of patients with psychiatric disorders face chronic, even life-long,
treatment with APDs, the risks of weight gain/obesity and other metabolic symptoms
are major considerations for individual APD maintenance treatment. This review will
focus on the effects of APDs on weight gain, appetite, insulin resistance and glucose
dysregulation, as well as relevant underlying mechanisms that may be help to prevent
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and treat weight gain, obesity, and other metabolic side-effects caused by APD
therapy.

WEIGHT GAIN AND OBESITY INDUCED BY ANTI-PSYCHOTICS
Weight gain/obesity side-effects: Typical vs Atypical APDs. It had been reported
since the 1950s that treatment with some typical APDs (such as chlorpromazine) is
associated with weight gain, however many psychiatrists still believe that atypical
APDs are associated with significant weight gain and obesity side-effects, but typical
APDs are not.14 For example, the commonly used typical APD, haloperidol, was once
believed to have a minimal weight gain side-effect.14 However, a recent report on the
European First-Episode Schizophrenia Trial (EUFEST) has clearly shown that one
year treatment with haloperidol caused clinically significant weight gain (≥ 7% from
baseline) in 53% of patients, with an average weight gain of 7.3 kg.15 A dramatic
weight gain (9.56 kg) was also observed in another study of first episode patients with
1 year treatment with haloperidol.16 Therefore, while certain atypical APDs (such as
olanzapine and clozapine) might lead to greater weight gain, typical APDs could also
lead to significant weight and other metabolic changes in patients.

Underestimation of weight gain and obesity side-effects has also been the case for
atypical APDs. In 2005, the NIH funded CATIE (The Clinical Anti-psychotic Trials
of Intervention Effectiveness) study reported the effects of atypical APDs olanzapine,
quetiapine, risperidone and ziprasidone on body weight over an 18 months period in
chronic schizophrenia patients who had an average of over 14 years’ APD medication
history.17 The CATIE study found that olanzapine treatment caused significant weight
gain (≥ 7% from baseline) in a higher proportion of patients (30%) than quetiapine
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(16%), risperidone (14%) and ziprasidone (7%). Patients treated with olanzapine also
gained more weight (average add 0.9 kg (2 lb) per month) than patients treated with
quetiapine (average add 0.23 kg (0.5 lb) per month) and risperidone (average add 0.18
kg (0.4 lb) per month), while ziprasidone treated patients lost body weight (average
lose 0.14 kg (-0.3 lb) per month).17 However, the subsequent EUFEST and CAFE
(Comparison of Atypical Anti-psychotics for First Episode) studies showed that these
atypical APDs caused more severe weight gain in first episode schizophrenia
patients.15, 18 The CAFE study reported that after a 12 week treatment, significant
weight gain (≥ 7% body weight) occurred in a large number of first episode
schizophrenia patients treated with olanzapine (59.8%), compared to risperidone
(32.5%) and quetiapine (29.2%). Furthermore, after 52 weeks’ treatment, 80% of
olanzapine-treated patients gained ≥ 7% body weight (with an average 1.76 kg (3.88
lb) per month), compared to 57.6% of risperidone- (with an average 1.28 kg (2.81 lb)
per month) and 50% of quetiapine-treated (with an average 1.29 kg (2.85 lb) per
month) patients.18 The EUFEST study confirmed that, after 12 months’ treatment,
olanzapine caused the most significant weight gain in first episode schizophrenia (in
86% of patients with an average 1.16kg (2.56 lb) per month) compared to quetiapine
(in 65% of patients with an average 0.88kg (1.94 lb) per month), amisulpride (in 63%
of patients with an average 0.81kg (1.78 lb) per month) and ziprasidone (in 37% of
patients with an average 0.4 kg (0.88 lb) per month).15 In another study of first
episode patients, dramatic weight gain was observed in all olanzapine (average 12.02
kg), risperidone (8.99kg) and haloperidol (9.56kg) treatment for 1 year.16 It is
interesting that ziprasidone and amisulpride have been widely regarded as atypical
APDs with low weight gain risk in previous studies;10 ziprasidone was even found to
cause weight loss in the CATIE study.17 Therefore, it is worth exploring why a lesser
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weight gain side-effect was observed in the CATIE study. The main difference
between these studies was that subjects in the CATIE study had a chronic APD
medication history (average over 14 years) compared to first episode patients in the
EUFEST and CAFE without previous APD medication.15, 17, 18 These clinical trials
indicate that previous studies on chronic schizophrenia patients may have
underestimated the magnitude of weight gain/obesity side-effects associated with
APDs. Furthermore, although mean weight gain and the incidence of clinically
significant weight gain may vary between APDs, olanzapine and clozapine have the
highest risk; accumulated evidence indicates that both typical and atypical APDs have
greater weight gain and other metabolic side-effects than placebo-level effects.9, 10, 15

Time-course of APD-induced weight-gain/obesity. Although various APDs cause
weight gain at different magnitudes, both typical and atypical APDs exhibit a similar
temporal course of weight gain that includes three stages: Stage 1, an early
acceleration stage in which APDs induce a rapid increase in body weight gain within
the first few months of treatment (e.g. about 3 months for clozapine, olanzapine,
risperidone, and haloperidol); Stage 2, a

middle stage in which body weight

continues to increase at a much steadier rate for at least the period of a year or longer;
and Stage 3, further treatment will lead to a plateau of weight gain, representing a
possible ‘ceiling effect’ of APDs, in which patients will maintain the heavier weight
with on-going APD treatment.19,

20

For example, first episode psychosis patients

treated with olanzapine or haloperidol gained weight rapidly during the first 12 weeks
(mean ± SD: olanzapine, 9.2±5.31 kg; haloperidol, 3.7±4.9 kg), then continued to
gain weight till a plateau was reached (olanzapine, 15.5±9.6 kg; haloperidol, 7.1±6.7
kg) at approximately 1 year and weight gain remained at this high level (olanzapine,

Page 7 of 31

15.4±10.0 kg; haloperidol, 7.5±9.2 kg) at the end of 2 years.20 The BMI changes
during the 2 year study period followed a pattern similar to that for weight gain; in the
olanzapine group the mean BMI increased from 23.6±4.8 (Mean ± SD) at the baseline
to 26.4±4.6 at 12 weeks, 28.8±4.5 at 1 year, and 28.3±4.0 at 2 years, compared with
haloperidol group with an increase from 23.9±4.5 at the baseline to 24.8±4.1 at 12
weeks, 26.2±4.3 at 1 year and 26.6±4.4 at 2 years.20 Several long-term studies
indicate that some APDs may take a much longer time to reach the plateau.19, 21, 22
This temporal course is well mimicked in an animal model of olanzapine-induced
weight gain.23, 24 Although the final weight plateau is often reached after several years,
accumulated evidence indicates that rapid weight-gain in the first few weeks (Stage 1)
of APD treatment is a strong indicator for the long-term outcome of weight gain and
obesity.25-27 Therefore, although the time-course of weight gain has been observed to
have a similar pattern in various APDs, the exact weight gain time-course induced by
a specific APD still remains for further research.

Are weight-gain and obesity side-effects of APD dose dependant? To date, the
possible relationship between APD dosages and associated weight gain has not been
systematically investigated. Simon and colleagues reviewed publications between
1975 and 2008 and suggested that olanzapine and clozapine appear to have
dose/serum concentration-dependant weight gain side-effects.28 For example, Perry
and colleagues reported associations of weight gain with both olanzapine dosages and
plasma concentrations.29 More recently, in an 8-week, randomized clinical trial of
olanzapine 10, 20, and 40 mg (oral) doses in 634 patients with schizophrenia or
schizoaffective disorder, a significant dose-related change in weight gain was found,
which suggested higher than standard doses of olanzapine may be associated with
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greater weight gain compared to standard doses.30 This was supported by a study into
long-acting olanzapine injection, in which clear dose-dependent changes of weight
gain were observed; a high dose (300mg every 2 weeks) had a higher weight gain
than medium (405 mg every 4 weeks) and low (150 mg every 2 weeks) doses in
schizophrenia patients.31 Risperidone-induced weight gain could be dose related to
some extent but data are contradictory, while no study assessed risperidone serum
concentrations in association with weight gain.28 Current evidence indicates that other
APDs including aripiprazole, amisulpride, quetiapine, sertindole and ziprasidone have
no dose-related metabolic effects, however no study assessed serum concentration of
these APDs.28 Therefore, prescribing the lowest possible effective doses, at least for
clozapine, olanzapine and risperidone, will be helpful in minimising the weight gain
side-effect.

THE

EFFECTS

OF

ANTI-PSYCHOTIC

MEDICATION

ON

APPETITE/FOOD INTAKE
Theoretically, body weight gain results from imbalance between energy intake and
energy expenditure, in which both over eating and/or less energy expenditure (such as
decreasing resting metabolism and activity) may contribute to overweight and obesity.
Over the past 15 years, accumulated data from both clinical and animal studies
suggest that increasing appetite and food intake, as well as delayed satiety signalling,
are key behavioural changes related to APD-induced weight gain/obesity.32-34 On the
other hand, there is less understanding of to what extent changes of resting
metabolism rate and activity/sedation affect weight gain associated with APD
medication, although current evidence suggests that they may play an important role
in the development of APD-induced weight gain.19, 35, 36
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Altered eating behaviours have been reported in a number of clinical studies with
treatment involving various APDs. Gothelf and colleagues first reported that
increased food intake, but not resting energy expenditure and physical activity, was
associated with olanzapine-induced weight gain in schizophrenia patients.37 A
randomized double-blind study has found that both clozapine and olanzapine are
associated with food craving and binge eating over the 6-week treatment period.38
Compared to those with clozapine, patients receiving olanzapine tended to have
higher rates of food craving (olanzapine 48.9% vs clozapine 23.3%) and binge eating
(olanzapine 16.7% vs clozapine 8.9%), which also occurred earlier (1 week vs 3
weeks for binge eating).38 Eating behaviour in patients treated with atypical APDs
(clozapine, olanzapine, risperidone, quetiapine or ziprasidone) were also compared
with health controls by recording appetite sensation before and after a standardized
breakfast using visual analogy scales, and found that: (1) atypical APD-treated
patients showed greater adiposity and a higher degree of hunger following the
standardized breakfast; and (2) patients had significantly higher cognitive dietary
restraint, disinhibition, and susceptibility to hunger than controls.33 The patients
treated with atypical APDs were also more reactive to external eating cues.34
Furthermore, a recent study reported that, consistent with the significant increase of
body weight, food consumption and disinhibited eating, one week treatment with
olanzapine enhanced both the anticipatory and consummatory reward response to
food rewards in the brain reward circuitry, including the inferior frontal cortex,
striatum and anterior cingulate cortex, but decreased activation in the brain region (the
lateral orbital frontal cortex) thought to inhibit feeding behaviour.39
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These clinical findings are confirmed in animal studies that APD-induced
hyperphagia is repeatedly found in animal models of APD-induced weight gain.23, 40-43
Furthermore, recently olanzapine has been found to selectively increase rat’s
responding to sucrose pellets in an operant conditioning without affecting freefeeding intake of sucrose; in contrast sibutramine (a noradrenaline/serotonin reuptake
inhibitor and a weight reducing agent) prevented the increase of rat’s responding to
sucrose pellets induced by olanzapine.44 It has been well established that the
hypothalamic arcuate nucleus (Arc) plays a crucial role in appetite and energy
homeostasis through activation of two distinct populations of anorexigenic and
orexigenic neurons: neurons that express appetite inhibiting cocaine- and
amphetamine-related transcript (CART) and pro-opiomelanocortin (POMC), and
neurons that express appetite stimulating agouti-related peptide (AgRP) and
neuropeptide Y (NPY).45 Using the animal model for olanzapine-induced weight gain,
it has been revealed that olanzapine elevated expression of appetite stimulating AgRP
and NPY and decreased appetite inhibiting POMC.46, 47 These results suggest that
patients treated with APDs may develop abnormal eating behaviours in response to
altered appetite sensations and increased susceptibility to hunger which may lead to a
positive energy balance and contribute to body weight gain.

INSULIN RESISTANCE, GLUCOSE DYSREGULATION, AND DIABETES
ASSOCIATED WITH ANTI-PSYCHOTIC MEDICATION
Effects of atypical APDs. Validated evidence over the past 20 years has indicated
that APD medication significantly increases the risk of insulin resistance, glucose
dysregulation and the development of T2DM.5,

48, 49

Although patients with

psychiatric disorders such as schizophrenia have been observed to have an increased
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risk of developing diabetes regardless of antipsychotics, suggesting that the disease
itself may be a predisposed risk factor,50-52 APD medication has been widely
recognized as a main contributor for these metabolic disorders.48, 49 An analysis of the
US FDA Adverse Event database also showed that adjusted report ratios for T2DM
were the following: olanzapine 9.6 (95% confidence interval (CI) 9.2-10.0),
risperidone 3.8 (3.5-4.1), quetiapine 3.5 (3.2-3.9), clozapine 3.1 (2.9-3.3), ziprasidone
2.4 (2.0-2.9), aripiprazole 2.4 (1.9-2.9), and haloperidol 2.0 (1.7-2.3), which suggests
differential risks of diabetes across various APDs.53

Owing to relatively short trial periods, many clinical trials have not been able to
capture most new cases of diabetes, however numerous studies have shown strong
relationships between APDs and indicators of insulin resistance and glucose
dysregulation.48,

54

In the CATIE study in chronic schizophrenia patients, fasting

blood glucose (FBG) was most elevated compared to baseline with olanzapine
(15.0±2.8 mg/dl; mean ± standard error), followed by quetiapine (6.8±2.5 mg/dl),
risperidone (6.7±2.0 mg/dl), perphenazine (5.2±2.0 mg/dl), and least elevated with
ziprasidone (2.3±3.9 mg/dl).17 The EUFEST study has reported a similar incident rate
of hyperglycemia among various APDs after one year treatment with haloperidol
(18%), amisulpride (21%), olanzapine (30%), quetiapine (22%) and ziprasidone
(22%), with a significant increase of fasting insulin level (haloperidol 2.0±1.4 mU/L,
amisulpride 8.6±3.1 mU/L, olanzapine 2.5±3.9 mU/L, quetiapine 2.1±1.2 mU/L and
ziprasidone 0.1±2.0 mU/L).15 Chronically elevated insulin levels and concurrent
hyperglycemia are consistent with insulin resistance, and may indicate T2DM.55 In
fact, numerous clinical studies have reported that chronic APD treatment increases
insulin-resistance. Using the homeostasis model assessment (HOMA) index for
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insulin resistance (HOMA-IR), chronic (8 weeks to 5 months) treatment with
olanzapine, clozapine and risperidone has been repeatedly reported to significantly
increase HOMA-IR,56-61 although risperidone was normally observed to have a lesser
effect on HOMA-IR.58, 60, 61 Furthermore, patients with chronic olanzapine treatment
also showed a greater decrease in insulin sensitivity during an oral glucose tolerance
test (OGTT) than those treated with risperidone.61 Using a frequently sampled
intravenous glucose tolerance test and minimal model analysis, significant insulin
resistance and impairment of glucose effectiveness were reported in non-obese
patients chronically treated with clozapine and olanzapine, but with a lesser effect in
patients treated with risperidone and quetiapine.62,

63

Recently, a two-step

euglycaemic, hyperinsulinaemic clamp procedure has been used to assess changes in
insulin sensitivity in non-diabetic patients with schizophrenia or schizoaffective
disorder treated with olanzapine or risperidone; it was found that both olanzapine and
risperidone treatment caused a decrement in insulin sensitivity.59 These results were
confirmed

in

numerous

animal

studies

using

the

HOMA-IR

index

or

euglycaemic/hyperinsulinaemic clamp procedures: chronic treatment with olanzapine
and clozapine caused insulin resistance, reduced insulin sensitivity and glucose
dysregulation.64-68

The effects of APDs using haloperidol as an example. Although over the past 15
years the metabolic side-effects of atypical APDs have attracted most of the attention,
there is evidence that treatment with some typical APDs also increases the risk of
insulin resistance, glucose dysregulation and T2DM.11,

49, 69, 70

Since they were

introduced to the clinics in the 1950s, chlorpromazine and thioridazine have been
repeatedly reported to cause abnormal glucose tolerance, insulin resistance and even

Page 13 of 31

T2DM.70-76 On the other hand, it was generally believed that haloperidol did not
increase the risk of insulin resistance and T2DM,49 however recent evidence from
clinical trials in first episode patients showed that haloperidol may have a higher risk
than originally thought. As discussed above, the EUFEST study has reported that one
year treatment of haloperidol has a similar incident rate of hyperglycemia and
increased fasting insulin levels to atypical APDs olanzapine and quetiapine.15 Another
randomized, double-blind trial in first episode schizophrenia patients also found that
both FBG and 2 hour post-prandial blood glucose (PPBG) were significantly
increased by a 6-week treatment with haloperidol (FBG, 6.8±14.1/dl, mean ± standard
deviation; PPBS, 6.7±12.6 mg/dl), olanzapine, (FBG, 6.6±12.7mg/dl; PPBS,
21.5±32.2 mg/dl) and risperidone (FBG, 4.3±12.5 mg/dl; PPBS, 21.0±23.4 mg/dl),
with a similar incidence rate of diabetes induced by APD treatment (haloperidol 9.7%,
olanzapine 11.4%, risperidone 9.1%) by WHO criteria.69 A one year treatment of
haloperidol in drug-naïve first episode patients showed a similarly increased insulin
level and insulin resistance index (HOMA-IR) as olanzapine and risperidone.77
Analyzing data from the Italian Health Search Database also showed that, in initially
non-diabetic and APD-free patients, the diabetic risk ratios were 12.4% (95% CI 6.324.5) for haloperidol, 18.7% (8.2-42.8) for risperidone, 20.4% (6.9-60.3) for
olanzapine, 33.7% (9.2-123.6) for quetiapine, and no significant difference between
various drug groups.78 These findings were confirmed by a large population-based
study conducted in Denmark, which included 345,937 patients treated with an APD
and 1,426,488 unexposed control subjects: a significantly higher relative risk
compared with the general population was observed in drug-naïve patients treated
with olanzapine (1.35, 95% CI 1.18-1.54), risperidone (1.24, 95% CI 1.09-1.40),
sertindole (9.53, 95% CI 1.34-67.63), perphenazine (1.60, 95% CI 1.45-1.77),
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ziprasidone (3.09, 95% CI 1.54-6.17), and haloperidol (1.32, 95% CI 1.17-1.49), but
not in patients treated with aripiprazole, amisulpride or quetiapine.79 These results
suggest that treatment with haloperidol, like chlorpromazine and thioridazine, is
associated an increased risk of glucose and insulin deregulation.

Indirect effects of APD-induced weight gain and obesity vs direct effects of APDs
on insulin resistance and glucose dysregulation. Given the well-established
association between obesity and insulin resistance and hyperglycemia, APD-induced
dysregulation of glucose homeostasis has been frequently linked to the high weight
gain and obesity propensity of these drugs. For example, many studies have found the
increased HOMA-IR induced by chronic treatment of olanzapine, clozapine or
risperidone was correlated with weight gain/adiposity.58,

77, 80

Weight gain and

adiposity were also found to be significantly correlated with changes in insulin
sensitivity in patients following a 12 week treatment with olanzapine and
risperidone.59 Recently, Kim et al. reported that body mass index contributed a quarter
to a third of the variance in insulin resistance in olanzapine-treated patients.81
However, growing evidence demonstrated that treatment with APDs, particularly
short-term treatment, can directly affect insulin resistance and glucose homeostasis
independent of weight gain.82 In fact, clinical studies have shown impaired glucose
regulation in some schizophrenia patients treated with APDs without weight gain.83
Insulin resistance has also been reported to be induced by olanzapine treatment within
days without weight gain.84, 85 Diabetic ketoacidosis has been reported in patients in
early treatment with various APDs and without weight gain.86 In APD-naïve
schizophrenia patients, two weeks’ treatment of olanzapine decreased insulin
secretory response to a hyperglycemic challenge, which suggests that olanzapine
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might directly impair pancreatic β-cell function.87 Data from animal studies also
showed that acute treatment, even a single acute dose, of olanzapine, risperidone or
clozapine can cause hyperglycemia and hyperinsulinemia, impair insulin-sensitivity,
and induce insulin-resistance.66, 88-91 An in vitro study also showed that olanzapine
and clozapine can directly decrease glucose-stimulated insulin secretion from
pancreatic β cells.92 Furthermore, olanzapine and clozapine can significantly decrease
the insulin-stimulated glucose transport rate by about 40% in 3T3-L1 adipocytes,
whereas clozapine and risperidone reduced the insulin-stimulated glucose transport
rate by about 40% in primary cultured rat adipocytes.93 Therefore, these typical APDs
may directly induce insulin resistance by directly impairing insulin-responsive
glucose resistance in adipocytes.93

Time course of APD-induced insulin dysregulation. Although a growing body of
evidence has shown that short-term/acute APD treatment decreases fasting plasma
insulin levels and attenuates glucose-stimulated insulin response,87,

88, 91, 94

as

discussed above, chronic treatment is associated with hyperinsulinemia, insulinresistance and T2DM.49, 59, 95 The apparent conflict in reports between chronic and
short-term APD treatment may be reconciled by a hypothesis of time-dependent
changes of APD-induced insulin dysregulation. This hypothesis is supported by a
recent report that found time-dependent changes of glucose-stimulated insulin
response in individuals with schizophrenia: decreased insulin levels during the first 2
weeks’ olanzapine treatment compared to their baseline levels, followed by a return to
baseline levels after 4 weeks’ treatment, and increased insulin response following 8
weeks’ olanzapine treatment.96 In another study in schizophrenia patients who started
or switched to a different APD for 3 months, a time-dependent worsening of plasma
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glucose levels was observed in subjects taking clozapine, olanzapine and quetiapine.97
A recent animal study also demonstrated that acute treatment of rats with olanzapine
showed both glucose dysregulation and insulin resistance, however rats treated
intermittently with olanzapine (once per week) showed a marked worsening in both
glucose dysregulation and insulin resistance over the time course of a 10 week
treatment.67 The mechanisms underlying this time-dependent change of APD-induced
insulin and glucose dysregulation have not been investigated however.

NEUROPHARMACOLOGICAL

MECHANISMS

FOR

APD-INDUCED

WEIGHT GAIN AND GLUCOMETABOLIC SIDE-EFFECTS
In contrast to typical APDs (such as haloperidol) that are largely potent and selective
D2 antagonists, atypical APDs have binding affinities for various neurotransmitter
receptors, such as dopamine D2, serotonin 5HT2A and 5HT2C, adrenergic α1-2,
muscarinic M1 and M3 and histamine H1 receptors98 Among these receptors, dopamine
D2 and 5-HT2 receptors play critical roles in the therapeutic effects of atypical
APDs.99, 100 Accumulated evidence has revealed that the antagonistic properties of
5HT2C and H1 receptors are involved in APD-induced weight gain.32, 101, 102 In fact,
among APDs, clozapine and olanzapine have the highest affinities for 5HT2C and H1
receptors, and have the highest risk of weight gain and obesity side-effects.36, 98, 103
Therefore, the neuropharmacological mechanisms reviewed here are mainly from
studies in olanzapine and clozapine. It is worth noting that, due to the variations in
receptor binding profiles between different APDs, the mechanisms underlying the
weight gain and glucometabolic side-effects might not be exactly the same between
various APDs.
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Over the past thirty years the 5-HT receptor has been revealed to regulate appetite and
body weight, mainly through acting at the hypothalamic 5-HT2C receptors.104 In fact,
5-HTergic neurons project to the hypothalamic POMC neurons that co-express 5HT2C receptors, and 5-HT has been found to influence appetite by activating
anorexigenic POMC neurons and melanocortin 4 receptors.104 Considering the finding
that olanzapine decreases expression of POMC in animal studies.46,

47

APDs may

therefore increase appetite by inhibiting POMC neurons through the 5-HT2C
receptors. It is interesting that 5-HT2C agonists reduce food intake by advancing
satiety, and these effects are reversed by 5-HT2C antagonists.105,

106

These results

suggested that blockade of 5-HT2C receptors could possibly be the mechanism for the
clinical findings that the treatment with both clozapine and olanzapine could induce
food craving and binge eating in patients.38 Furthermore, the role of 5-HT2C in APDinduced weight gain was confirmed by an animal study which showed that the initial
(5 days) increase in weight gain and food intake associated with olanzapine treatment
could be mimicked by combining a 5-HT2C antagonist (SB243213) with haloperidol,
but not by an H1 antagonist alone or combined with haloperidol.107 However, there is
clear evidence that 1-week and 12 weeks treatment with olanzapine reduces the
expression of hypothalamic H1 receptors, and H1 receptor changes have been
correlated with increased food intake and weight gain in rats.24 Olanzapine and
clozapine have been reported to activate hypothalamic AMPK pathway via H1
receptors to increase food intake and body weight gain.108 Olanzapine has also been
reported to regulate feeding behaviour in rats by modulating histaminergic
neurotransmission.109 The role of the H1 receptor in APD-induced weight gain has
also been supported by findings that co-treatment of betahistine (an H1 agonist and an
H3 antagonist) can significantly reduce olanzapine-induced weight gain in both
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schizophrenia patients and animals.110-112 It has also been postulated that different
neural mechanisms are responsible for the three stages of weight gain induced by
APDs.19

APD affinity for the Muscarinic M3 receptor has been identified as most closely
linked to its diabetic side-effects.113-115 and can even be used to predict its
diabetogenic liability.113 Consistently, olanzapine and clozapine, two of the APDs
associated with a high risk of insulin resistance, glucose dysregulation and diabetic
side-effects, possess the highest M3 receptor binding affinity.116 M3 receptors play a
crucial role in the regulation of insulin secretion through both the peripheral and
central cholinergic pathways

117

. An in vitro study has shown that olanzapine and

clozapine can impair cholinergic-stimulated insulin secretion.92 A recent animal study
found that a single subcutaneous injection of darifenacin (a selective M3 muscarinic
antagonist) significantly decreased insulin response to glucose challenge compared to
control.118 M3 receptors are widely expressed in the hypothalamic arcuate (Arc) and
ventromedial (VMH) nuclei, and the dorsal vagal complex of the brainstem, brain
regions well-documented for their role in insulin and glucagon secretion and glucose
homeostasis.119,

120

Recently, we found that a 2-week treatment with olanzapine

decreased fasting insulin levels and correlated with an increase in M3 receptor binding
density in the Arc, VMH, and DVC.121 In addition, acute central treatment with
olanzapine via intracerebroventricular infusion induces hepatic insulin resistance and
increased hypothalamic AMPK expression.122 Results from the two studies suggest
that olanzapine may block M3 receptor signalling pathways in the brain, thus
impacting insulin production and insulin resistance. Therefore, APDs may act through
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both peripheral and central M3 antagonism to impair compensatory insulin response,
resulting in diabetes.

Since the introduction of APDs in the 1950s, binding at dopamine D2 receptors
(antagonism or partial agonism) remains the only mechanism common to therapeutic
efficacy of all APDs.100 There is evidence that both atypical and typical APDs can
cause weight gain and other metabolic side-effects, particularly recent clinical data
from studies in first episode patients that demonstrated haloperidol (a potent and
selective D2 antagonist) is associated with weight gain, insulin resistance, glucose
dysregulation side-effects as discussed above; it is therefore reasonable to propose D2
receptors as a possible common mechanism underlying these side-effects. Although it
has been the subject of fewer investigations, there is some evidence supporting the
involvement of D2 receptors in APD-induced weight gain, insulin resistance, glucose
dysregulation side-effects. As discussed above, only combined treatment of a 5-HT2C
antagonist with haloperidol can mimic olanzapine-induced weight gain.107 A
relationship between a functional promoter region polymorphism in DRD2 and weight
gain induced by olanzapine and risperidone has reported in first episode
schizophrenia.123 Dopamine and D2 receptors are key components of the reward
system controlling desire for food and hence body weight regulation.124 Our previous
study found that D2 receptor density was significantly lower in the rostral part of the
caudate putamen in obese mice compared to lean mice.125 It is well established that
blockade of dopamine D2 receptor activity in the mesolimbic and nigrostriatal
pathways is the common mechanism of APD action,100, 126 these pathways are also
key pathways for food reward.127 In fact, a reduced striatal activation was detected by
fMRI during reward anticipation due to appetite-provoking in chronic schizophrenia
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with APD treatment.128 Therefore, APDs may increase appetite and food intake by
acting on dopamine D2-mediated reward.127 It is interesting that D2-like receptors are
also expressed in pancreatic β-cells which function to inhibit glucose-stimulated
insulin secretion,129 and permanent lack of D2 receptor mediated inhibition (such as in
D2 knock out mice Drd2-/-) eventually results in glucose intolerance.130 It has been
reported that a single subcutaneous injection of raclopride (a D2/D3 selective
antagonist) can enhance insulin secretion and marginally decrease insulin
sensitivity.118 Therefore, this may provide a mechanism to explain why chronic
treatment of some typical APDs (such as haloperidol) leads to glucose dysregulation
hyperinsulinemia, and eventually diabetes.

SUMMARY
Over the past 20 years, it has been established that treatment with atypical APDs is
associated with serious weight gain, obesity, and other metabolic side effects such as
insulin resistance, glucose dysregulation and T2DM, however the metabolic sideeffects associated with some typical APDs are possibly underestimated. Emerging
evidence over the past 5-6 years from the studies in first episode psychotic and drug
naïve patients show that some commonly used typical APDs (such as haloperidol)
may also course significant weight gain, insulin resistance, glucose dysregulation, and
even T2DM, particularly under chronic treatment. In fact, although some atypical
APDs, particularly clozapine and olanzapine, have a higher liability than others in
inducing metabolic side-effects, current evidence has indicated that all APDs have a
greater weight gain and various metabolic side-effects than placebo-level effects.
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It is worth noting that variations in weight gain and other metabolic side-effects are
observed not only among APDs, but the marked individual variations have also been
observed in all reported clinical studies and that, irrespective of the APD, some
subjects lose weight, some maintain weight and some gain weight.15, 17 It is also worth
noting note that not all weight gain is detrimental. For those patients who are
underweight prior to APD treatment, possibly reflecting that their psychotic illness
has caused them to neglect themselves, weight gain associated with APD is beneficial
if the medication results in these individuals returning to a pre-morbid and healthy
weight.131 This individual variation could be related to both genetic and nongenetic
factors (such as gender, age and initial body weight/BMI etc.).132, 133 Although there is
no reliable biomarker for prediction of weight gain, several studies have identified
female gender, younger age and a low BMI prior to the first APD treatment as risk
factors for APD-induced weight gain and obesity.133-136 A diagnosis of
undifferentiated schizophrenia or schizophrenia spectrum disorder was also identified
as a possible predictor for APD-induced weight gain.133,

136

Since APD-induced

weight gain has a time-dependent development, and particularly rapid weight gain in
the first few weeks of APD treatment is a good indicator for a long-term outcome of
weight gain and obesity,19,

27

weight monitoring during the early phase of APD

therapy is crucial for prevention of this serious side-effect. It is important to note that
insulin resistance and glucose dysregulation may develop independently of weight
gain, therefore monitoring only weight gain is not enough, and a periodic monitoring
of blood sugar may also be required during APD therapy, particularly for drugs with
high diabetic liabilities such as olanzapine and clozapine. Although current evidence
suggests that multiple neurotransmitter receptors such as 5-HT2C, histamine H1,
muscarinic M3 (and possibly also dopamine D2 receptors), are involved in weight
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gain/obesity and insulin and glucose dysregulation associated with APDs, one
important issue that needs to be investigated is how these neurotransmitter systems
interact during the time-dependent development of these side-effects. An improved
understanding of the mechanisms underlying the time-dependent development of
these metabolic side-effects could help in designing better strategies to prevent and
treat these devastating side-effects and their associated cardiovascular disease, stroke
and premature death.
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